AF
AVTX icon

Amalgamated Financial’s Avalo Therapeutics AVTX Stock Holding History

Amalgamated Financial’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$7K Buy
+3
New +$7.54K ﹤0.01% 2935

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Amalgamated Financial's AVTX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Avalo Therapeutics (AVTX) in Q1 2022: 3 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #2935 among its holdings.

65 funds tracked by Wall St. Rank hold AVTX as of Q1 2022.

  • Amalgamated Financial held 3 shares of Avalo Therapeutics worth $7K as of Q1 2022.
  • Avalo Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Avalo Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2935 holding.
  • 65 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.